Reza Soleimani

Mr. Reza Soleimani

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
RSReza Soleimani
Reza Soleimani
MKMehdi Khourssaji
Mehdi Khourssaji
DGDamien Gruson
Damien Gruson
Hector Rodriguez-VillalobosHector Rodriguez-Villalobos
Hector Rodriguez-Villalobos
MBMathilde Berghmans
Mathilde Berghmans
BKBenoit Kabamba-Mukadi
Benoit Kabamba-Mukadi
Background Since December 2019 we have been in the battlefield with a new threat to the humanity, known as SARS‐CoV‐2, which causes COVID‐19, characterized by viral pneumonia. It may be asymptomatic or cause various symptoms, ranging from flu like symptoms to ARDS and eventually death. At present, the only reliable test for COVID‐19 diagnosis is RT‐qPCR. Assessing the immune response against SARS‐CoV‐2 could increase the detection sensitivity of infected population. Hereby, we report the performances of a fully automated chemiluminescent immunoassay (CLIA) on 276 serum samples. Methods One hundred samples obtained from COVID‐19 negative subjects (COVID‐19 free) were analyzed to evaluate diagnostic specificity of antibody (Ab) detection. Thereafter, 176 samples obtained from 125 patients with confirmed COVID‐19 (COVID‐19 patients) were selected to assess the diagnostic sensitivity of the CLIA. All samples were analyzed on MAGLUMITM 800 platform. Results All COVID‐19 free samples had Ab levels below the cut‐off values. Hence, the diagnostic specificity was estimated at 100% (95%CI= 96.3‐100.0; PPV= 100%). By the 18th day from the onset of symptoms we reached to an optimal diagnostic sensitivity (more than 95.0 %) In fact, the diagnostic sensitivity increased over time and between 15 to 25 days after symptoms onset, reached to 95.5% (95% CI= 84.9‐99.2). Conclusion The new automated CLIA analyzer appeared to be a robust and reliable method to measure specific Ab against COVID‐19 at a high throughput. Our data suggest that combining Ab and nucleic acid detection could increase the diagnostic sensitivity.

30 October 2019 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
PDF file
RSReza Soleimani
Reza Soleimani
JFJulien Favresse
Julien Favresse
TRTatiana Roy
Tatiana Roy
DGDamien Gruson
Damien Gruson
CFCatherine Fillée
Catherine Fillée
Background: The correct identification of the macro-B12 interference (macroforms) is paramount to avoid potential erroneous clinical decisions. Our objectives were to determine whether immunoassays are affected by the presence of macro-B12 and to validate a polyethylene glycol (PEG) precipitation procedure to detect it. Methods: Sixty-two serum samples obtained from healthy volunteers were analyzed to determine recovery and reference intervals (RIs) following PEG precipitation. Thereafter, 50 serum samples with very high levels of B12 (>1476 pmol/L) were randomly selected to search for macro-B12 interferences. Serum samples obtained from healthy volunteers and related PEG aliquots were analyzed on a Cobas® immunoassay. Patients’ samples were analyzed on both Cobas® and Architect® immunoassays. Finally, samples suspected to contain macro-B12 were analyzed by size-exclusion chromatography (SEC) to confirm the presence of macro-B12. Results: Recovery and post-PEG RIs determined on a Cobas 8000® in healthy volunteers ranged from 68.3% to 108.4% and from 122.1 to 514.4 pmol/L, respectively. Fifteen samples (30%) were found to show macro-B12 while using the recovery criteria, and nine samples (18%) while using the post-PEG RI. The other immunoassay ran on the Architect i2000® was also affected by the presence of macro-B12. Size-exclusion chromatography studies confirmed the presence of macro-B12 (immunoglobulin-B12 complexes). Conclusions: The prevalence of macro-B12 in elevated B12 samples is high. We suggest to systematically screen for the presence of macro-B12 with PEG precipitation procedure in samples with elevated B12 levels to avoid potential misdiagnosis or harmful clinical consequences.

22 April 2020 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PDF file
SMSamy Mzougui
Samy Mzougui
JFJulien Favresse
Julien Favresse
RSReza Soleimani
Reza Soleimani
CFCatherine Fillée
Catherine Fillée
DGDamien Gruson
Damien Gruson
Background: Biotin is currently a matter of concern for laboratories using biotin-streptavidin-based immunoassays. Biotin interferences have been reported for high-sensitive troponin T (hsTnT) and thyroid-stimulating hormone (TSH) assays. We aimed to evaluate the new generation of hsTnT and TSH electrochemiluminescent immunoassays announced to be less sensitive to biotin. Methods: Firstly, we assessed the analytical performances of new generation assays (imprecision, bias, total error, limit of quantification) and compared previous and new generation assays in the absence of biotin. Secondly, we challenged both generations of assays with samples spiked with seven different biotin levels. The efficiency of new generation assays was also compared to the streptavidin beads treatment. Results: New generation assays presented suitable analytical performances. Previous and new generations of hsTnT and TSH assays were commutable in the absence of biotin. In the presence of biotin, we confirmed that previous generation assays were affected by biotin concentration as low as 40.5 ng/mL and that new generation assays were not affected up to the announced tolerance threshold of 1200 ng/mL. After the streptavidin beads treatment, we observed a higher imprecision for both parameters and a constant 10% negative bias for TSH compared to new generation assays. Conclusions: New generation of electrochemiluminescent immunoassays appears as a reliable systematic solution to prevent biotin interference for hsTnT and TSH testing.

19 May 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
RSReza Soleimani
Reza Soleimani
CDCorentin Deckers
Corentin Deckers
THTe‐Din Huang
Te‐Din Huang
PBPierre Bogaerts
Pierre Bogaerts
SEStéphanie Evrard
Stéphanie Evrard
ODOlivier Denis
Olivier Denis
The current reliable recommended test for coronavirus disease 2019 (COVID‐19) diagnosis is quantitative reverse‐transcription polymerase chain reaction (RT‐qPCR). Rapid antigen test devices could be useful as they are less expensive, faster without the need of specialized laboratories to perform the test. We report the performances of two rapid immunochromatographic antigen testing devices compared with RT‐qPCR for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) detection in nasopharyngeal samples. We carried out a lateral‐flow tests study on 401 nasopharyngeal swab samples from nonduplicated suspected COVID‐19 subjects. An equal volume of universal transport medium tubes‐containing samples (dilution ratio = 1:15) were added to the manufacturer's extraction buffer solution (dilution ratio = 1:2) and analyzed on BioSpeedia COVID19Speed‐Antigen Test and on Abbott Panbio™ COVID‐19 Ag Rapid Test, devices. Qualitative results were compared to those obtained by the RT‐qPCR (Allplex™ SARS‐CoV‐2 Assay Seegene). Based on our data, the overall sensitivity for BioSpeedia and Panbio devices was estimated at 65.5% and 75.0%, respectively. The sensitivity was greater for cycle threshold values less than 25 achieving 90.4 and 96.8 for BioSpeedia and Panbio devices, respectively. A perfect specificity of 100.0% was observed for both devices.

28 July 2019 in Clinical Case Reports
Verified
Journal Article
Open access
RSReza Soleimani
Reza Soleimani
KBKarl Brousmiche
Karl Brousmiche
JFJulien Favresse
Julien Favresse
VHVincent Haufroid
Vincent Haufroid
DGDamien Gruson
Damien Gruson
PWPierre Wallemacq
Pierre Wallemacq
In the last decade, our knowledge about OTC drug intoxication has been expanded much further relative to previous years, though the absence of antidotes in some cases results in healthcare professionals using symptomatic treatment. This case report reminds the reader of the importance of clinical and toxicology laboratories in the management of acute salicylate intoxication in order to avoid hemodialysis.

10 January 2022 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
CDCorentin Deckers
Corentin Deckers
RSReza Soleimani
Reza Soleimani
ODOlivier Denis
Olivier Denis
PBPierre Bogaerts
Pierre Bogaerts
CBCatherine Berhin
Catherine Berhin
THTe-Din Huang
Te-Din Huang
In order to elaborate a new national challenge panel of resistant Gram-negative bacilli and Gram-positive cocci strains for the validation of routine antimicrobial susceptibility testing (AST) methods, an interlaboratory evaluation was organised. The results of 12 well-characterised multidrug-resistant strains tested by nine laboratories using local disk diffusion (DD) and automated AST (AUST) methods were compared with the reference broth microdilution method. Overall categorical agreement ranged from 70% to 100% both for DD and AUST and was >90% for all but one strain for all antibiotics. Our multicentre AST study showed good reproducibility and the panel can be used as national resistant reference strains for routine AST validation.